Combination therapy for inducing immune response to disease
The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3× anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
IBC Pharmaceuticals, Inc.
A C C C C A C A C C C A C A C A A A A C A C C A
A61K C07K C07K C07K C07K A61K C07K A61K C07K C07K C07K A61K C07K A61K C07K A61K A61K A61K A61K C07K A61K C07K C07K A61K
inventional inventional inventional inventional inventional additional additional inventional additional additional inventional inventional inventional inventional additional inventional inventional inventional additional inventional inventional inventional additional additional
Hans J. Chien-Hsing David M. Diane Edmund A.
Hansen Chang Goldenberg Rossi Rossi